A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancer.
Eyre TA, Collins GP, Gupta A, Coupe N, Sheikh S, Whittaker J, Wang LM, Campo L, Soilleux E, Tysoe F, Cousins R, La Thangue N, Folkes LK, Stratford MRL, Kerr D, Middleton MR.
Eyre TA, et al. Among authors: la thangue n.
Cancer. 2019 Jan 1;125(1):99-108. doi: 10.1002/cncr.31791. Epub 2018 Oct 17.
Cancer. 2019.
PMID: 30332497
Free article.
Clinical Trial.